Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10278987 | 0.78 | KDM4E (0.59) | ALDH1A1KDM4ESMN1; SMN2LMNAMEN1 | |
| SCHEMBL5870445 | 0.77 | KDM4E (0.58) | ALDH1A1KDM4ESMN1; SMN2LMNAMEN1 | |
| SCHEMBL15563767 | 0.75 | HCAR2 (0.41) | ALDH1A1KDM4ELMNAELANEMEN1 | |
| SCHEMBL15565115 | 0.75 | LMNA (0.48) | ALDH1A1KDM4ELMNAMEN1KMT2A | |
| SCHEMBL18256063 | 0.73 | SMN1; SMN2 (0.55) | ALDH1A1KDM4ESMN1; SMN2LMNAMEN1 | |
| SCHEMBL2114938 | 0.72 | KDM4E (0.63) | ALDH1A1KDM4ESMN1; SMN2LMNAMEN1 | |
| SCHEMBL1417913 | 0.70 | KDM4E (0.81) | ALDH1A1KDM4ESMN1; SMN2LMNAMEN1 | |
| SCHEMBL12866914 | 0.70 | KDM4E (0.50) | ALDH1A1KDM4ESMN1; SMN2LMNAMEN1 | |
| SCHEMBL311900 | 0.69 | KDM4E (0.64) | ALDH1A1KDM4ESMN1; SMN2LMNAMEN1 | |
| SCHEMBL4957306 | 0.69 | KDM4E (0.59) | ALDH1A1KDM4ESMN1; SMN2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1178969-B1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2005-07-13 | — | — | EP | disclosed |
| US-20030195240-A1 | Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| US-6479531-B1 | Gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-11-12 | — | — | US | disclosed |
| EP-1178969-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-02-13 | — | — | EP | disclosed |
| WO-2001085167-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PROTON PUMP INHIBITORS AND GASTRIN/CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| WO-2000027823-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195240-A1 | Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands | GIPR, CCKAR, CCKBR | ALDH1A1 4620/4885KDM4E 4090/4885SMN1; SMN2 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.